In this section, the IO Essentials faculty members provide short video segments discussing the recognition and management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitor therapies. In some cases, they discuss specific aspects of irAE recognition and management within the context of their specific tumor type.
In this video, chairperson Brianna Hoffner, MSN, AOCNP, RN, of the University of Colorado, describes the origins of the IO Essentials Initiative and reviews the range of resources available on the initiative’s site.
In this video, chairperson Brianna Hoffner, MSN, AOCNP, RN, of the University of Colorado, discusses the growing range of immune-related adverse events associated with immune checkpoint inhibitors (ie, pan “itis”).
In this video, Eric D. Whitman, MD, FACS, of the Atlantic Health System, discusses the genesis and features of the IO Essentials Initiative.
In this video, Eric Whitman, MD, FACS, of the Atlantic Health System, discusses optimal use of corticosteroids for immune-related adverse events.
In this video, Eric D. Whitman, MD, FACS, of the Atlantic Health System, discusses the evaluation of the most common symptoms occurring in patients receiving immune checkpoint inhibitors.
In this video, Eric D. Whitman, MD, FACS, of the Atlantic Health System, discusses the concept of “pan-itis” associated with immune checkpoint inhibitors and how to address it in practice.
In this video, Eric D. Whitman, MD, FACS, of the Atlantic Health System, comments on how his office triages irAEs associated with immune checkpoint inhibitors.
In this video, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California San Francisco, discusses the use of immune checkpoint inhibitors in classical Hodgkin lymphoma.
In this video, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California San Francisco, discusses the recognition and management of hepatotoxicity in patients receiving immune checkpoint inhibitors.
In this video, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California San Francisco, discusses the recognition and management of nephritis in patients receiving immune checkpoint inhibitors.
In this video, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California San Francisco, discusses the recognition and management of hypothyroidism in patients receiving immune checkpoint inhibitors.
In this video, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California San Francisco, discusses the risk of GvHD with PD-1 inhibition after alloHSCT.
In this video, Laura J. Zitella, MS, RN, ACNP-BC, AOCN®, of the University of California San Francisco, discusses the recognition and management of diabetes in patients receiving immune checkpoint inhibitors.
In this video, Jessica Mitchell, APRN, CNP, MPH, of the Mayo Clinic, discusses the identification and management of peripheral neuropathy associated with immune checkpoint inhibitors in the setting of pre-existing oxaliplatin-induced peripheral neuropathy.
In this video, Jessica Mitchell, APRN, CNP, MPH, of the Mayo Clinic, discusses the identification and management of rash associated with immune checkpoint inhibitors vs that associated with EGFR inhibitors.
In this video, Jessica Mitchell, APRN, CNP, MPH, of the Mayo Clinic, discusses the identification and management of diarrhea/colitis associated with immune checkpoint inhibitors vs that seen with chemotherapy.
In this video, Jessica Mitchell, APRN, CNP, MPH, of the Mayo Clinic, discusses the process for differentiating liver dysfunction from immunotherapy vs other causes (such as disease progression) in patients with GI malignancies.
In this video, Jessica Mitchell, APRN, CNP, MPH, of the Mayo Clinic, discusses the differential diagnosis of shortness of breath caused from pneumonitis from immunotherapy vs other causes (such as disease progression) in patients with GI malignancies.
In this video, Mollie Lehner Reed, MSN, RN, ACPP-BC, of Tennessee Oncology, discusses the evaluation of liver dysfunction in patients receiving immune checkpoint inhibitors.
In this video, Mollie Lehner Reed, MSN, RN, ACPP-BC, of Tennessee Oncology, discusses the evaluation and management of diarrhea/colitis in patients with CRC receiving immune checkpoint inhibitors.
In this video, Mollie Lehner Reed, MSN, RN, ACPP-BC, of Tennessee Oncology, discusses the evaluation and management of neuropathy in patients with CRC receiving immune checkpoint inhibitors.
In this video, Mollie Lehner Reed, MSN, RN, ACPP-BC, of Tennessee Oncology, discusses the evaluation and management of pneumonitis in patients with GI cancers receiving immune checkpoint inhibitors.
In this video, Laura Wood, RN, MSN, OCN, of the Cleveland Clinic, explains how the diarrhea from immunotherapy is different from the diarrhea patients experience with VEGF tyrosine kinase inhibitors.
In this video, Laura Wood, RN, MSN, OCN, of the Cleveland Clinic, reviews the laboratory testing that should be undertaken in patients receiving immune checkpoint inhibitors.
In this video, Laura Wood, RN, MSN, OCN, of the Cleveland Clinic, reviews the laboratory evaluation and management of myalgias and arthralgias in patients receiving immune checkpoint inhibitors.
In this video, Laura Wood, RN, MSN, OCN, of the Cleveland Clinic, discusses the evaluation and management of nephritis in patients with RCC who are receiving immune checkpoint inhibitors.
In this video, Casey Fazer, PA-C, of the Mayo Clinic, discusses recognition and management of mucositis in patients with Head-and-Neck Cancer receiving immune checkpoint inhibitors.
In this video, Casey Fazer, PA-C, of the Mayo Clinic, discusses counseling to assure adequate nutrition for patients with Head-and-Neck Cancer experiencing xerostomia or mucositis from immune checkpoint inhibitors.
In this video, Casey Fazer, PA-C, of the Mayo Clinic, discusses the management of skin toxicities from immune checkpoint inhibitors in patients with pre-existing skin issues.
In this video, Casey Fazer, PA-C, of the Mayo Clinic, discusses the triage of edema in patients receiving immune checkpoint inhibitors.
In this video, Casey Fazer, PA-C, of the Mayo Clinic, discusses counseling on embryo-fetal toxicity and fertility issues in patients receiving immune checkpoint inhibitors.
In this video, Christine Kim, NP, of the University of California, San Francisco, discusses recognition and management of thyroiditis in patients receiving immune checkpoint inhibitors.
In this video, Christine Kim, NP, discusses recognition and management of diabetes in patients receiving immune checkpoint inhibitors.
In this video, Christine Kim, NP, of the University of California, San Francisco, discusses management of infusion reactions in patients receiving immune checkpoint inhibitors.
In this video, Christine Kim, NP, of the University of California, San Francisco, discusses recognition and management of encephalitis in patients receiving immune checkpoint inhibitors.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the recognition and management of hypophysitis.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the recognition and management of adrenal insufficiency.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the recognition and management of pneumonitis.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the recognition and management of nephritis
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the evaluation and management of shortness of breath in patients with lung cancer receiving immune checkpoint inhibitors.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the evaluation and management of headache in patients receiving immune checkpoint inhibitors.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the recognition and management of myalgias/arthralgias.
In this video, Marianne J. Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, of Yale University, discusses the evaluation and management of visual changes and eye complications associated with immune checkpoint inhibitor therapies.
In this video, chairperson Brianna Hoffner, MSN, AOCNP, RN, of the University of Colorado, discusses the management of skin toxicities associated with use of immune checkpoint inhibitors.
In this video, chairperson Brianna Hoffner, MSN, AOCNP, RN, of the University of Colorado, reviews the differential diagnosis and management of confusion in patients receiving immune checkpoint inhibitors.
In this video, chairperson Brianna Hoffner, MSN, AOCNP, RN, reviews the differential diagnosis and management of myalgia in patients receiving immune checkpoint inhibitors.
In this video, chairperson Brianna Hoffner, MSN, AOCNP, RN, discusses the risk-benefit discussion in patients receiving adjuvant immunotherapy for high-risk melanoma.
In this video, Eric D. Whitman, MD, FACS, of the Atlantic Health System, explains how he discusses the benefits and risks of adjuvant immune checkpoint inhibitor therapy with patients.
In this video, Paula Anastasia, RN, MN, AOCN®, of Cedars-Sinai Medical Center, Los Angeles, describes the use of immune checkpoint inhibitors in MSI-High/dMMR tumors.
.
In this video, Paula Anastasia, RN, MN, AOCN®, of Cedars-Sinai Medical Center, Los Angeles, describes the recognition and management of neuropathy in patients receiving ICIs, particularly for gynecologic cancers.
In this video, Paula Anastasia, RN, MN, AOCN®, of Cedars-Sinai Medical Center, Los Angeles, describes the recognition and management of diabetes in patients receiving ICIs, particularly in patients with baseline issues with glucose control.
In this video, Paula Anastasia, RN, MN, AOCN®, of Cedars-Sinai Medical Center, Los Angeles, describes the recognition and management of thyroiditis in patients receiving ICIs.
In this video, Paula Anastasia, RN, MN, AOCN®, of Cedars-Sinai Medical Center, Los Angeles, describes the recognition and management of GI toxicity in patients receiving ICIs.
